Module 27

General Properties
Below we list the number of gene sets from which the module was composed was originally composed, and the number of genes and experiments that it contains. Clicking on the number of genes will display a detailed list of all the genes in the module. Clicking on the number of experiments will display a detailed list of all the experiments in the module.
Num gene sets:	2
Num genes:	356 (see 3065 additional genes for this module)
Num experiments:	914 (331 induced, 583 repressed)
Parent module:	64
Children modules:	None

Gene sets
Below we list the gene sets from which the module was originally composed. Clicking on a gene set will display all the genes associated with that gene set. Also listed are all the other modules in which the gene set participates.
transmembrane receptor activity
receptor activity

Enriched clinical annotations
For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched.
Clinical annotation	Category	P-value	Hits	Hits(%)	Module hits in category	Arrays in annotation	Arrays
Acute leukemia (Leukemia*)	Leukemia*	5.8e-41	116	19.9	582	141	1945
Cancer and cell line (Leukemia*)	Leukemia*	5.8e-41	116	19.9	582	141	1945
Cancer (Leukemia*)	Leukemia*	5.8e-41	116	19.9	582	141	1945
Hematologic cancer and cell line (Leukemia*)	Leukemia*	5.8e-41	116	19.9	582	141	1945
Hematologic cancer (Leukemia*)	Leukemia*	5.8e-41	116	19.9	582	141	1945
Hematologic samples and cell lines (Leukemia*)	Leukemia*	5.8e-41	116	19.9	582	141	1945
Leukemia (Leukemia*)	Leukemia*	5.8e-41	116	19.9	582	141	1945
Leukemia or leukemia cell line (Leukemia*)	Leukemia*	5.8e-41	116	19.9	582	141	1945
Monocytes (Leukemia*)	Leukemia*	5.8e-41	116	19.9	582	141	1945
Non-tumor liver tissue (Liver cancer)	Liver cancer	9.7e-29	71	75.5	94	76	207
Liver tissue (Liver cancer*)	Liver cancer*	3.7e-28	93	28.0	331	187	1945
Liver tissue, cancer or cell line (Liver cancer*)	Liver cancer*	6.6e-26	93	28.0	331	197	1945
Cancer and cell line (Liver cancer)	Liver cancer	1.1e-25	86	98.8	87	126	207
Hepatitis infected liver (Liver cancer*)	Liver cancer*	9.1e-20	73	22.0	331	156	1945
Hematologic cancer and cell line (Stimulated PBMC)	Stimulated PBMC	6.0e-15	22	70.9	31	30	182
Macrophages (Stimulated PBMC)	Stimulated PBMC	6.0e-15	22	70.9	31	30	182
Cancer (Liver cancer)	Liver cancer	6.9e-15	75	86.2	87	115	207
Hematologic samples and cell lines (B lymphoma)	B lymphoma	1.3e-13	69	81.1	85	121	245
Adenocarcinoma (Liver cancer)	Liver cancer	4.6e-12	65	74.7	87	97	207
Hepatocellular carcinoma (Liver cancer)	Liver cancer	2.9e-11	67	77.0	87	104	207
Lymphoma (B lymphoma)	B lymphoma	1.3e-09	48	56.4	85	77	245
Activated B like DLBCL (B lymphoma)	B lymphoma	4.8e-08	15	48.3	31	30	245
Invasive liver tumor (Liver cancer)	Liver cancer	3.6e-07	30	34.4	87	38	207
Breast tissue or cancer (Breast cancer*)	Breast cancer*	3.1e-06	40	12.0	331	118	1945
Female hormonal tissue or cancer (Breast cancer*)	Breast cancer*	3.1e-06	40	12.0	331	118	1945
Breast cancer cell line (Breast cancer)	Breast cancer	3.5e-06	14	30.4	46	17	152
Cell line (Breast cancer)	Breast cancer	4.0e-06	20	43.4	46	30	152
Cell line (B lymphoma)	B lymphoma	5.5e-06	13	15.2	85	14	245
Lung carcinoid (Lung cancer)	Lung cancer	7.1e-06	14	21.2	66	20	276
Hematologic samples (Stimulated PBMC*)	Stimulated PBMC*	1.8e-05	46	13.8	331	152	1945
Lymphocytes (Stimulated PBMC*)	Stimulated PBMC*	1.8e-05	46	13.8	331	152	1945
Primary blood mononuclear cells (Stimulated PBMC*)	Stimulated PBMC*	1.8e-05	46	13.8	331	152	1945
Fast doubling (20-40) cell lines (NCI60)	NCI60	3.4e-05	35	97.2	36	90	122
Adenocarcinoma (Breast cancer*)	Breast cancer*	3.9e-05	36	10.8	331	112	1945
Breast cancer (Breast cancer*)	Breast cancer*	3.9e-05	36	10.8	331	112	1945
Cancer (Breast cancer*)	Breast cancer*	3.9e-05	36	10.8	331	112	1945
Female hormonal cancer (Breast cancer*)	Breast cancer*	3.9e-05	36	10.8	331	112	1945
Female hormonal cancer cell line (Breast cancer)	Breast cancer	4.0e-05	12	26.0	46	15	152
Cell line (Liver cancer)	Liver cancer	4.8e-05	11	12.6	87	11	207
B. petrussis A2 stimulated immune cells (Stimulated PBMC)	Stimulated PBMC	5.4e-05	5	22.7	22	5	144
Liver cancer cell line (Liver cancer)	Liver cancer	0.0001	10	11.4	87	10	207
Normal tissue (Liver cancer)	Liver cancer	0.0001	13	13.8	94	14	207
Hematologic cancer and cell line (Stimulated immune*)	Stimulated immune*	0.0002	20	6.0	331	53	1945
Hematologic samples and cell lines (Stimulated immune*)	Stimulated immune*	0.0002	20	6.0	331	53	1945
Macrophages (Stimulated immune*)	Stimulated immune*	0.0002	20	6.0	331	53	1945
Monocytes (Stimulated immune*)	Stimulated immune*	0.0002	20	6.0	331	53	1945
Female hormonal tissue, cancer or cell line (Breast cancer*)	Breast cancer*	0.0003	40	12.0	331	141	1945
Diffuse large B cell lymphoma - DLBCL (B lymphoma)	B lymphoma	0.0003	25	80.6	31	126	245
Breast tissue, cancer or cell line (Breast cancer*)	Breast cancer*	0.0003	40	12.0	331	142	1945

Enriched GO annotations
For each GO annotation, we tested whether it was enriched in the set of genes of the module. Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of the module's genes in which they appear. We also show the fraction of the module's genes with the given GO annotation that are included in this module ('Hits (%)' column). For completeness, we also list the total number of genes in the module ('Module genes' column), total number of genes in the compendium in which the corresponding annotation is present ('Genes in annotation' column), and the total number of genes in the compendium ('Genes' column).
GO annotation	P-value	Hits	Hits(%)	Module genes	Genes in annotation	Genes
receptor activity	0	356	100	356	582	4566
transmembrane receptor activity	1.7e-271	290	81.4	356	448	4566
signal transducer activity	1.5e-182	321	90.1	356	1026	4566
integral to plasma membrane	3.8e-107	214	60.1	356	612	4566
porin activity	3.1e-103	140	39.3	356	235	4566
channel/pore class transporter activity	1.7e-95	160	44.9	356	351	4566
G-protein coupled receptor activity	9.8e-71	100	28.0	356	170	4566
rhodopsin-like receptor activity	4.9e-60	86	24.1	356	147	4566
signal transduction	3.5e-59	194	54.4	356	831	4566
cell communication	7.9e-57	213	59.8	356	1030	4566
cell surface receptor linked signal transduction	2.6e-42	94	26.4	356	259	4566
transmembrane receptor protein tyrosine kinase activity	1.4e-40	47	13.2	356	62	4566
transmembrane receptor protein kinase activity	6.1e-39	48	13.4	356	68	4566
response to biotic stimulus	1.2e-37	138	38.7	356	600	4566
response to stress	3.7e-35	157	44.1	356	792	4566
protein kinase activity	3.6e-34	54	15.1	356	102	4566
G-protein coupled receptor protein signaling pathway	9.8e-33	81	22.7	356	245	4566
immune response	4.0e-29	109	30.6	356	469	4566
conjugation without cellular fusion	5.6e-28	59	16.5	356	152	4566
hematopoietin/interferon-class (D200-domain) cytokine receptor activity	2.4e-26	31	8.7	356	42	4566
peptide receptor activity\, G-protein coupled	2.7e-26	36	10.1	356	58	4566
peptide receptor activity	8.7e-25	34	9.5	356	55	4566
immunoglobulin receptor activity	2.9e-20	21	5.8	356	25	4566
interleukin receptor activity	2.1e-18	21	5.8	356	28	4566
interleukin binding	6.4e-17	19	5.3	356	25	4566
eye photoreceptor cell fate commitment	8.6e-17	23	6.4	356	38	4566
glutamate receptor activity	1.1e-16	24	6.7	356	42	4566
extracellular ligand-gated ion channel activity	4.5e-16	21	5.8	356	33	4566
transmembrane receptor protein tyrosine kinase signaling pathway	4.8e-16	26	7.3	356	52	4566
compound eye morphogenesis (sensu Drosophila)	9.0e-16	23	6.4	356	41	4566
post-embryonic morphogenesis	9.0e-16	23	6.4	356	41	4566
post-embryonic development	1.8e-15	23	6.4	356	42	4566
G-protein signaling\, coupled to cyclic nucleotide second messenger	8.3e-15	26	7.3	356	57	4566
amine receptor activity	1.3e-14	19	5.3	356	30	4566
cell adhesion receptor activity	2.1e-14	17	4.7	356	24	4566
excitatory extracellular ligand-gated ion channel activity	5.2e-14	15	4.2	356	19	4566
protein tyrosine kinase activity	5.4e-14	37	10.3	356	120	4566
integrin complex	1.9e-13	15	4.2	356	20	4566
defense response	2.2e-13	58	16.2	356	272	4566
response to extracellular stimulus	2.7e-13	85	23.8	356	500	4566
ligand-gated ion channel activity	9.3e-13	22	6.1	356	48	4566
synaptic transmission	3.1e-12	34	9.5	356	116	4566
G-protein signaling\, coupled to IP3 second messenger (phospholipase C activating)	9.5e-12	21	5.8	356	48	4566
defense/immunity protein activity	1.3e-11	31	8.7	356	103	4566
vesicle-mediated transport	4.1e-11	44	12.3	356	196	4566
scavenger receptor activity	9.6e-11	9	2.5	356	9	4566
integrin-mediated signaling pathway	1.0e-10	14	3.9	356	23	4566
cellular defense response	2.1e-10	20	5.6	356	50	4566
cytosolic calcium ion concentration elevation	2.2e-10	14	3.9	356	24	4566
cell-matrix adhesion	5.0e-10	15	4.2	356	29	4566
Fc receptor activity	9.0e-10	9	2.5	356	10	4566
nicotinic acetylcholine-activated cation-selective channel activity	9.0e-10	9	2.5	356	10	4566
cAMP-mediated signaling	1.7e-09	15	4.2	356	31	4566
transmembrane receptor protein phosphatase activity	1.7e-09	10	2.8	356	13	4566
antigen presentation\, peptide antigen	5.5e-09	10	2.8	356	14	4566
antigen processing	5.5e-09	10	2.8	356	14	4566
G-protein signaling\, coupled to cAMP nucleotide second messenger	9.5e-09	16	4.4	356	39	4566
acetylcholine receptor activity	1.0e-08	8	2.2	356	9	4566
nicotinic acetylcholine-gated receptor-channel complex	1.0e-08	8	2.2	356	9	4566
nucleotide receptor activity	1.5e-08	10	2.8	356	15	4566
ion channel activity	4.1e-08	28	7.8	356	117	4566
neurotransmitter receptor activity	4.9e-08	11	3.0	356	20	4566
coreceptor activity	4.9e-08	8	2.2	356	10	4566
ligand-dependent nuclear receptor activity	6.8e-08	13	3.6	356	29	4566
cell adhesion	8.9e-08	41	11.5	356	222	4566
inflammatory response	1.1e-07	26	7.3	356	108	4566
G-protein chemoattractant receptor activity	1.3e-07	9	2.5	356	14	4566
ephrin receptor activity	1.6e-07	8	2.2	356	11	4566
thermoregulation	2.5e-07	25	7.0	356	105	4566
MHC class I receptor activity	5.1e-07	7	1.9	356	9	4566
response to pest/pathogen/parasite	6.2e-07	32	8.9	356	163	4566
G-protein signaling\, adenylate cyclase inhibiting pathway	6.7e-07	9	2.5	356	16	4566
alpha-type channel activity	7.4e-07	28	7.8	356	133	4566
T-cell activation	9.3e-07	37	10.3	356	207	4566
lymphocyte activation	1.1e-06	37	10.3	356	209	4566
GABA-A receptor activity	1.3e-06	9	2.5	356	17	4566
antigen binding	1.4e-06	6	1.6	356	7	4566
steroid hormone receptor activity	1.4e-06	11	3.0	356	26	4566
chemokine binding	4.1e-06	7	1.9	356	11	4566
sugar binding	4.2e-06	15	4.2	356	51	4566
protein amino acid phosphorylation	4.9e-06	38	10.6	356	230	4566
antigen presentation\, endogenous antigen	5.2e-06	6	1.6	356	8	4566
antigen processing\, endogenous antigen via MHC class I	5.2e-06	6	1.6	356	8	4566
carbohydrate binding	5.5e-06	15	4.2	356	52	4566
humoral defense mechanism (sensu Invertebrata)	6.0e-06	18	5.0	356	72	4566
endocytosis	7.4e-06	13	3.6	356	41	4566
activation of MAPK	9.2e-06	7	1.9	356	12	4566
GPI-anchored membrane-bound receptor	1.4e-05	6	1.6	356	9	4566
receptor mediated endocytosis	1.8e-05	7	1.9	356	13	4566
humoral immune response	2.8e-05	23	6.4	356	118	4566
negative regulation of adenylate cyclase activity	3.4e-05	6	1.6	356	10	4566
sensory perception	4.2e-05	82	23.0	356	700	4566
interleukin-1\, Type I\, activating receptor activity	5.1e-05	5	1.4	356	7	4566
taxis	5.2e-05	17	4.7	356	76	4566
MAPKKK cascade	6.3e-05	9	2.5	356	25	4566
induction of programmed cell death	8.7e-05	20	5.6	356	102	4566
heterophilic cell adhesion	8.9e-05	12	3.3	356	44	4566
two-component signal transduction system (phosphorelay)	9.1e-05	9	2.5	356	26	4566
chemotaxis	0.0001	16	4.4	356	73	4566
death	0.0001	46	12.9	356	342	4566
interleukin-1 receptor activity	0.0001	5	1.4	356	8	4566
response to water	0.0001	5	1.4	356	8	4566
metabotropic glutamate\, GABA-B-like receptor activity	0.0001	6	1.6	356	12	4566
secretin-like receptor activity	0.0001	6	1.6	356	12	4566

Visual display

Below is a visual display of the module. Shown are those arrays in which the module's genes significantly change, and the direction of change (induction/repression) in each array is indicated (middle, labeled 'Module changes'; red/green row). The arrays that correspond to the significant clinical attributes are also shown (top; brown rows). The gene sets that compose the module are also shown (left) along with an indication of the membership of the module genes in these gene sets.

You can also view the images within GeneXPress by loading the module gxp file file.

Note: Since there are 914 experiments, this image does not display the individual experiment names, but rather condenses each experiment to a single pixel without displaying its name. You can fully view the image for this module within GeneXPress, by loading any of the four files mentioned in the line above

>4x